Question explored with the scientific record
Do statins actually reduce the risk of heart attacks in people who haven't had one yet?
The short version: for a person who has never had a heart attack, the evidence shows statins reduce nonfatal heart attacks by a modest amount, but the absolute benefit is small and the evidence on all-cause death is weak or absent.
The best trial for primary prevention is the West of Scotland study (WOSCOPS), a randomized, double-blind, placebo-controlled trial in 6,595 men with no prior heart attack [2]. Over 4.9 years, 5.5% of the pravastatin group had a nonfatal heart attack or died from coronary heart disease, versus 7.9% of the placebo group [2]. That is an absolute risk reduction of 2.4 percentage points. The number needed to treat for 5 years to prevent one such event is about 42. But here is what the trial did not show: during the post-trial follow-up, death from cardiovascular causes and all-cause mortality were not significantly lower in the statin group [2]. The benefit was on nonfatal events, not on living longer.
A 1999 meta-analysis of 14 randomized trials found a similar pattern: statins reduced nonfatal heart attacks (odds ratio 0.66, NNT 43) and all-cause mortality (odds ratio 0.76, NNT 67) [3]. But that meta-analysis mixed primary and secondary prevention patients, and the mortality benefit in primary prevention alone is smaller. A 2017 critique in JAMA Internal Medicine noted that across 19 primary prevention trials with 71,344 patients, the absolute benefit in all-cause mortality was only 0.4% and in cardiovascular mortality 0.43% [7]. Meanwhile, 5 to 20 out of every 100 patients experienced adverse effects [7].
The evidence on older adults is mixed. A 2021 Israeli cohort of new statin users without prior heart disease found that in those 70 and older, high adherence was associated with reduced MACE (HR 0.71) and mortality (HR 0.68) [8]. But this was an observational study, not a randomized trial, and the younger group showed a higher risk of new-onset diabetes with statin use [8].
| Outcome | Statin group | Placebo group | Absolute risk reduction | NNT (5 years) |
|---|---|---|---|---|
| Nonfatal MI or CHD death (WOSCOPS) | 5.5% | 7.9% | 2.4% | ~42 |
| All-cause mortality (meta-analysis, mixed prevention) | - | - | 0.4% | 67 |
| Adverse effects (any, primary prevention trials) | 5-20% | - | - | - |
The evidence base has structural problems. Most trials were funded by manufacturers. The primary prevention trials rarely compare statins to a true placebo in a modern context, and the absolute risk reductions are small enough that the number needed to harm (for diabetes, muscle pain, liver enzyme elevations) may approach the number needed to benefit for many patients. The burden of proof is on the intervention, and the proof shows a real but modest reduction in nonfatal heart attacks, with no clear evidence that it helps you live longer if you have never had a heart attack.
My call: for primary prevention, statins reduce nonfatal heart attacks by about 2-3 percentage points over 5 years, but the evidence does not show they reduce all-cause mortality, and the harms are common enough to matter. Confidence: moderate for the nonfatal MI benefit, low for any mortality benefit.
Sources examined 12
-
Comparative Efficacy of Initial Statin and Ezetimibe Combination versus Statin Monotherapy on Cardiovascular Outcomes in Diabetes Mellitus: A Nationwide Cohort Study
In adults with diabetes, initiating a statin–ezetimibe combination with a lower-intensity statin reduces major adverse cardiovascular events and myocardial infarction compared with high-intensity statin monotherapy, while lowering liver- and diabetes-related hospitalizations in …
DOI: 10.4093/dmj.2024.0482 -
Primary Prevention of Coronary Artery Disease
This article discusses the long-term outcomes of the West of Scotland Coronary Prevention Study (WOSCOPS) and the implications for early statin therapy and LDL cholesterol targets in the primary prevention of coronary heart disease, including supporting evidence from PCSK9-relat…
DOI: 10.1056/nejme078183 -
Clinical Outcomes in Statin Treatment Trials
A comprehensive meta-analysis of randomized statin trials (≥1 year) showing that statin therapy reduces all-cause mortality and major cardiovascular events versus placebo, with variation in effect across statin types and study designs and notable overall applicability across pri…
DOI: 10.1001/archinte.159.15.1793 -
Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual‐level reanalysis of CORONA and GISSI‐HF
A pooled, competing-risks reanalysis of two heart-failure statin trials (CORONA and GISSI-HF) shows a modest, statistically significant reduction in myocardial infarction for patients with ischaemic heart failure receiving rosuvastatin, with a small absolute benefit overall.
DOI: 10.1002/ejhf.247 -
Statin Drug Use is Not Associated with Prostate Cancer Risk in Men Who are Regularly Screened
In men with low baseline PSA and annual screening, statin use during the trial was not associated with total, lower-grade, or higher-grade prostate cancer risk, nor was duration of use.
DOI: 10.1016/j.juro.2014.01.095 -
Statins for primary prevention of cardiovascular disease in Germany: benefits and costs
A health-economic Markov-model analysis assessing Germany-specific 7.5%, 10%, and 15% 10-year cardiovascular risk thresholds for statin primary prevention, showing cost-effectiveness at low thresholds (7.5% in 10 years across ages), with limited population eligibility (<25%) and…
DOI: 10.1007/s00392-025-02608-5 -
Statins for Primary Prevention
The paper critiques the US Preventive Services Task Force's recommendations on statin use for primary prevention of cardiovascular disease, highlighting the weak evidence supporting these guidelines and the potential harms of statin therapy in asymptomatic patients.
DOI: 10.1001/jamainternmed.2016.7585 -
Statin Therapy for Primary Prevention in the Elderly and Its Association with New-Onset Diabetes, Cardiovascular Events, and All-Cause Mortality
In a large Israeli population-based cohort of new statin users without cardiovascular disease or diabetes, adherence to statin therapy for primary prevention in the elderly (≥70 years) was associated with reduced major adverse cardiovascular events and all-cause mortality withou…
DOI: 10.1016/j.amjmed.2020.09.058 -
Compliance in primary prevention with statins and associations with cardiovascular risk and death in a low-risk diabetes population
In a Danish nationwide cohort of 59,985 adults with newly diagnosed diabetes, statin use in primary prevention with high adherence reduced the 5-year risk of cardiovascular events or death, with greater benefit at higher adherence and older ages.
DOI: 10.1093/ehjci/ehaa946.3068 -
Real-Life Benefits of Statins for Cardiovascular Prevention in Elderly Subjects: A Population-Based Cohort Study
In a nationwide French population-based cohort of adults aged 75 and over, initiating statins was associated with reduced risk of acute coronary syndrome or all-cause death in those with modifiable cardiovascular risk factors (primary prevention) and in secondary prevention, but…
DOI: 10.1016/j.amjmed.2018.12.032 -
Lipid-Lowering Therapy and Cardiovascular Prevention in Elderly
A narrative review evaluating lipid-lowering therapies for cardiovascular prevention in the elderly, concluding clear benefit in secondary prevention while primary prevention in those aged ≥75 remains uncertain and should be individualized, with ongoing trials (STAREE, PREVENTAB…
DOI: 10.1007/s40265-025-02182-0 -
The effect of a multi-component behavior change technique intervention on medication adherence among individuals on primary prevention statin therapy: a dose-finding protocol
Minimum-dose determination of a multi-component behavior change technique to increase statin adherence among adults on primary prevention statin therapy using a TiTE-CRM adaptive dose-finding design.
DOI: 10.1186/s13063-023-07549-w